Question Bank › The feared thing keeps not happening

The feared thing keeps not happening

The feared thing keeps not happening: management confronts a specific live worry with current evidence running against i

Calls Tested
994
Answered YES
93
Hit Rate
9.4%
rare by design

Qifu Technology, Inc. (QFIN) — this company's answers

NO on the Q2 2023 call 2023-08-22 C+
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录,判断是否存在一个具体的、公司特定的负面担忧,并且管理层用已经观察到的业务证据来反驳这一担忧。 首先,寻找担忧。在电话会议中,分析师的问题和管理的陈述中,是否有对公司特定的担忧?例如,关于贷款期限缩短、提前还款、收入增长与贷款量增长不匹配、宏观环境不确定性等。分析师Alex Ye问到了贷款量增长强劲但收入增长较弱的问题,这暗示了担忧收入增长跟不上。管理层解释是由于贷款期限缩短和提前还款。这算是一个担忧吗?但这是关于收入增长的问题,不是明确的负面结果。另一个分析师Frank Zheng问到了额外拨备和贷款期限改善措施。管理层回答拨备政策保守,会有回拨,并采取措施改善期限。这似乎是对风险的担忧。 更具体地,是否有担忧公司增长不可持续或需求下降?在回答Emma Xu的问题时,管理层提到注意到短期消费贷款下降,但自己的贷款余额在7月和8月继续增长,并提到结构性变化,高质量用户提前还款,低质量用户需求稳定,以及中小企业用户更活跃。这似乎是在反驳需求下降的担忧。 但我们需要确认这是否是一个“具体的、公司特定的恐惧”,并且管理层用“已经观察到的证据”来反驳。在电话会议中,管理层自己提到了“宏观环境不确定性”和“消费者信贷复苏缓慢”,但这是宏观的。分析师的问题更多是关于财务指标和风险。 再仔细看,在回答Alex Ye的问题时,管理层承认贷款期限缩短导致收入增长慢,但说正在采取措施改善。这似乎承认了问题,而不是反驳。在回答Frank Zheng时,管理层说会有回拨,并采取措施改善期限,但这是计划,不是已经观察到的证据。 在回答Emma Xu时,管理层说“我们的贷款余额继续增长”,这是已经观察到的证据,反驳了需求下降的担忧。但这是否是分析师明确提出的担忧?Emma Xu问的是“贷款需求在第三季度如何”,并提到消费贷款下降,这暗示了担忧需求疲软。管理层回答自己的贷款余额在增长,并提到结构性变化,这算是反驳。 但我们需要判断这是否是“具体的、公司特定的恐惧”。分析师没有直接说“我们担心你的需求会下降”,而是问需求情况。管理层回应说自己的需求在增长,这算是反驳吗?但管理层也承认宏观环境疲软,但自己的业务表现好。 另外,在电话会议中,管理层提到了“提前还款”问题,这影响了收入,但管理层说正在改善,并给出了具体措施和观察到的改善(从4月到7月提前还款率下降)。这算是对担忧的反驳吗?但担忧是收入增长慢,管理层承认了,并说会改善,但改善是未来的,不是已经观察到的。 再考虑是否有其他担忧,比如关于监管、竞争等。没有明显。 我认为,这个电话会议中,分析师的问题更多是关于财务表现和风险,但并没有一个明确的、具体的负面结果被担忧,比如“客户流失”、“产品失败”等。管理层也没有明确说“市场担心我们X,但我们已经看到Y”。相反,管理层承认了一些挑战(如提前还款、期限缩短),并说正在采取措施,但措施是未来的。 因此,可能不符合“管理层用已经观察到的证据反驳”的条件,因为管理层更多是承认问题并给出计划。 但注意,在回答Emma Xu时,管理层说“我们的贷款余额继续增长”,这是已经观察到的,反驳了需求下降的担忧。但这是否是分析师明确提出的担忧?分析师问的是“贷款需求”,并提到宏观数据,这隐含了担忧。管理层用实际数据反驳了。 然而,这个担忧是宏观的,不是公司特定的。分析师没有说“我们担心你的公司需求下降”,而是问整体需求。管理层说自己的需求在增长,这算是公司特定的反驳。 但我们需要判断这是否是“具体的、公司特定的恐惧”。我认为,这个担忧是“消费信贷需求疲软可能影响公司增长”,这是公司特定的,因为公司依赖贷款需求。管理层用实际增长反驳了。 但管理层也承认了宏观不确定性,并调整了全年目标,这似乎是在承认担忧。 再仔细看,管理层在回答中提到了“结构性变化”,并说“我们预期增加对中小企业用户的投入”,这似乎是计划,不是已经观察到的。 我认为,这个电话会议中,没有出现一个明确的、被分析师反复追问的、公司特定的负面结果,比如“客户流失”、“监管打击”等。分析师的问题更多是关于财务指标的解释,而不是担忧。 因此,答案应该是NO。 但为了保险,再检查一下是否有其他担忧。在回答Frank Zheng时,关于拨备,管理层说会有回拨,这是已经发生的(过去有回拨),但未来也有。这不算反驳。 在回答Yada Li时,关于回购,没有担忧。 所以,我认为没有符合条件。 最终答案:NO。

← Back to the full QFIN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company — a worry that is live on this call, evident either because analysts keep probing it or because management itself names it as a concern others hold — AND does management push back on that worry by pointing to CURRENT, ALREADY-OBSERVED evidence from the business showing that the feared outcome is, so far, NOT materializing? Answer YES when BOTH halves come through in the transcript as one coherent dynamic, in whatever form fits the business: (1) A NAMED, COMPANY-SPECIFIC FEAR THAT IS LIVE NOW. The worry is concrete and attached to this company — for example: that demand will fall off after an unusually strong stretch; that a major customer, contract, or partner will shrink, leave, or not renew; that a competitor, new technology, or cheaper alternative will take the company's business; that a key product, franchise, or pricing level is about to erode; that recent growth is a one-time bulge that will reverse; or another identifiable adverse outcome the market has been bracing for. The fear must be visible on the call itself — analysts returning to it in their questions, or management acknowledging in its own words that this is what people are worried about — not merely a generic risk factor or ordinary caution. (2) MANAGEMENT ANSWERS WITH OBSERVED BEHAVIOR, NOT REASSURANCE. Management responds by citing things that have ALREADY HAPPENED or are happening now — customers renewing, reordering, or expanding when they were expected to leave; demand holding or growing through the period when a drop-off was predicted; the threatened product, customer, or pricing actually performing in the recent period; competitive losses that have not shown up in real accounts; the feared cliff period arriving and being cleared — described with enough concrete substance (who, what, how much, or compared to when) that the rebuttal rests on evidence from the business rather than on confidence, promises, arguments about why the fear is illogical, or projections that the future will be fine. Answer NO if no specific company-attached worry is visible on the call — a routinely healthy company fielding ordinary questions is not this. Answer NO if the fear is visible but management's response is mainly reassurance, optimism, plans, or forecasts without already-observed evidence against it. Answer NO if the evidence shows the feared outcome IS materializing and management is excusing, minimizing, or promising to fix it. Answer NO if the worry is only broad macro or industry-wide gloom with nothing specific to this company's own business. Answer NO if management concedes the fear is valid and pivots to a different story instead of countering it. Answer NO if the counter-evidence is only a single vague assertion (such as 'demand remains strong') with no concrete grounding in what has actually occurred. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
AVTR Avantor, Inc. Q2 2024 2024-07-26 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
GL Globe Life Inc. Q1 2024 2024-04-23 F
MNKD MannKind Corporation Q4 2023 2024-02-27 C
NICE NICE Ltd. Q4 2023 2024-02-22 B+
TYGO Tigo Energy, Inc. Q4 2023 2024-02-14 F
MET MetLife, Inc. Q4 2023 2024-02-01 B+
BBVA Banco Bilbao Vizcaya Argentaria, S.A. Q4 2023 2024-01-30 B+
TBLA Taboola.com Ltd. Q3 2023 2023-11-08 B+
GMED Globus Medical, Inc. Q3 2023 2023-11-07 B
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
MAC The Macerich Company Q3 2023 2023-10-31 D
LNTH Lantheus Holdings, Inc. Q2 2023 2023-08-03 C+
SITM SiTime Corporation Q2 2023 2023-08-02 C+
TREX Trex Company, Inc. Q2 2023 2023-07-31 B+
REYN Reynolds Consumer Products Inc. Q1 2023 2023-05-10 C
DOCN DigitalOcean Holdings, Inc. Q1 2023 2023-05-09 C+
ULCC Frontier Group Holdings, Inc. Q1 2023 2023-05-07 C+
AKR Acadia Realty Trust Q4 2022 2023-05-06 B+
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
EPR EPR Properties Q1 2023 2023-04-27 C+
MEDP Medpace Holdings, Inc. Q1 2023 2023-04-25 B+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
POOL Pool Corporation Q4 2022 2023-02-16 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
REGN Regeneron Pharmaceuticals, Inc. Q4 2022 2023-02-03 C
HBAN Huntington Bancshares Incorporated Q4 2022 2023-01-20 B
A Agilent Technologies, Inc. Q4 2022 2022-11-21 B+
PCTY Paylocity Holding Corporation Q1 2023 2022-11-05 A
TT Trane Technologies plc Q3 2022 2022-11-02 A
APOG Apogee Enterprises, Inc. Q2 2023 2022-09-20 A
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
ZBRA Zebra Technologies Corporation Q2 2022 2022-08-02 C+
LIN Linde plc Q2 2022 2022-07-28 B+
SHW The Sherwin-Williams Company Q2 2022 2022-07-27 D
JBHT J.B. Hunt Transport Services, Inc. Q2 2022 2022-07-19 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
KFY Korn Ferry Q4 2022 2022-06-22 B
SE Sea Limited Q1 2022 2022-05-17 F
DCGO DocGo Inc. Q1 2022 2022-05-14 C
ZVIA Zevia PBC Q1 2022 2022-05-12 B
EGHT 8x8, Inc. Q4 2022 2022-05-10 C+
CCRN Cross Country Healthcare, Inc. Q1 2022 2022-05-04 B
ABNB Airbnb, Inc. Q1 2022 2022-05-03 B+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
BSX Boston Scientific Corporation Q1 2022 2022-04-27 B
CCK Crown Holdings, Inc. Q1 2022 2022-04-26 C+
FR First Industrial Realty Trust, Inc. Q1 2022 2022-04-21 A
SDIG Stronghold Digital Mining, Inc. Q3 2021 2021-11-30 F
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
HSY The Hershey Company Q3 2021 2021-10-28 C
PEP PepsiCo, Inc. Q3 2021 2021-10-05 B
GDS GDS Holdings Limited Q2 2021 2021-08-17 C+
PTVE Pactiv Evergreen Inc. Q2 2021 2021-08-08 C+
SPG Simon Property Group, Inc. Q2 2021 2021-08-02 B
GLW Corning Incorporated Q2 2021 2021-07-27 B+
DOV Dover Corporation Q2 2021 2021-07-20 B+
VLRS Controladora Vuela Compañía de Aviación, Q2 2021 2021-07-16 B+
MAR Marriott International, Inc. Q2 2018 2018-08-07 B
VALE Vale S.A. Q2 2018 2018-07-26 B
FICO Fair Isaac Corporation Q3 2018 2018-07-26 C+
ORAN Orange SA Q2 2018 2018-07-26 B
KIM Kimco Realty Corporation Q2 2018 2018-07-26 B+
TRUE TrueCar, Inc. Q1 2018 2018-05-08 C
TGNA TEGNA Inc. Q1 2018 2018-05-08 B+
CVS CVS Health Corporation Q1 2018 2018-05-02 B+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
MIDD The Middleby Corporation Q4 2017 2018-02-28 C
SBUX Starbucks Corporation Q1 2018 2018-01-26 C
AVT Avnet, Inc. Q2 2018 2018-01-25 B
GURE Gulf Resources, Inc. Q3 2017 2017-11-14 F
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
MKTX MarketAxess Holdings Inc. Q3 2017 2017-10-25 C+
PII Polaris Inc. Q3 2017 2017-10-24 C+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BCRX BioCryst Pharmaceuticals, Inc. Q1 2017 2017-05-07 B
ICFI ICF International, Inc. Q1 2017 2017-05-06 B+
CGNT Cognyte Software Ltd. Q4 2016 2017-03-09 D
BDC Belden Inc. Q4 2016 2017-02-02 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
SEM Select Medical Holdings Corporation Q1 2016 2016-05-06 C+
LPSN LivePerson, Inc. Q1 2016 2016-05-04 B
UVE Universal Insurance Holdings, Inc. Q1 2016 2016-05-03 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
VRTS Virtus Investment Partners, Inc. Q1 2016 2016-04-29 D
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
BX Blackstone Inc. Q1 2016 2016-04-21 B
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

TGI · Q2 2017 → YESThe question is: Is there a specific negative outcome that investors/analysts/market are worried about for THIS company, live on this call, and does management push back with CURRENT, ALREADY-OBSERVED...YES The specific, company-attached fear that is live on the call is that Triumph will continue to face large performance-related charges, cash burn on development programs, and failure to stabilize margins/cash flow despite the transformation (a worry analysts repeatedly probe via questions on the $80M risk, free-cash-use guidance, 747-8/C-17/G650 headwinds, and red programs). Management directly counters it by citing already-observed evidence: Q2 operating income of $70.
ULCC · Q1 2023 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors/analysts/market have been worried about for THIS company, live on this call, AND does management push back with CURRENT, ALREADY-OB...YES The transcript shows a live, company-specific worry about pilot staffing shortages (tied to network changes and new contracts elsewhere) and customer churn/retention due to lower satisfaction scores. Management directly counters both with current evidence: pilot surplus and attrition on target for staffing, plus over 90% repeat business for retention.
HOLX · Q4 2017 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company, and does management push back on that worry by poin...YES The transcript shows a live, company-specific fear centered on Cynosure: investors and analysts are worried that the acquisition will not deliver sustainable growth, that recent sequential declines reflect a lasting salesforce collapse or competitive erosion, and that the business will continue underperforming expectations rather than turning around.

More from the question bank

Doors opening at the company's own gatesReporting the counterparty's growth as its oSecond proving already underwayNew normal declared and staffedBigger than they can carry aloneDemand arrived first, the company is growingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.